Fact CheckerSign in

NCT05815342Completed

OP5-005 Using Omnipod 5 in Adults With Type 2

Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes

Source: ClinicalTrials.gov · Last updated 29 Sept 2025

Brief summary (registry, in English)

This is a single arm, multi-center, prospective study that will evaluate the safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes requiring insulin therapy.

Status (registry)
Completed
Study type
Interventional
Enrollment
343 (actual)
First submitted
21 Mar 2023
Start date
Apr 2023
Primary completion date
Mar 2024
Lead sponsor
Insulet Corporation
NCT number
NCT05815342

What you commit to

  • Study type: Interventional
  • Participants enrolled: 343
  • From Apr 2023 to the primary completion date, Mar 2024
  • 21 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Use of an AID pump in automated mode within 3 months prior to screening
  • Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
  • Any planned surgery during the study which could be considered major in the opinion of the investigator
  • History of more than 1 severe hypoglycemic event in the 6 months prior to screening
  • History of more than 1 episode of diabetic ketoacidosis (DKA) or Hyperosmolar hyperglycemic syndrome (HHS) in the 6 months prior to screening; unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis
  • Has taken oral or injectable steroids within 8 weeks prior to screening or plans to take oral or injectable steroids during the study
  • Pregnant or lactating, planning to become pregnant during the study, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal)
  • Participation in another clinical study using an investigational drug or device other than the Omnipod 5 in the 30 days prior to screening or intends to participate during the study period

Other illness

  • Any medical condition which in the opinion of the investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and/or eating disorders (i.e. anorexia/bulimia)
  • Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement

Lab values

  • Blood disorder or dyscrasia within 3 months prior to screening, including use of hydroxyurea, which in the investigator's opinion could interfere with determination of HbA1c

Other

  • Plans to receive blood transfusion over the course of the study
  • Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment
  • Participant is an employee of Insulet, an Investigator or Investigator's study team, or immediate family member (spouse, biological or legal guardian, child, sibling, parent) of any of the aforementioned

Who the study is looking for

  • Age at time of consent 18-75 years
  • Diagnosed with type 2 diabetes, on current insulin regimen for at least 3 months prior to screening (i.e. Basal-bolus, basal only or pre-mix)
  • Basal bolus (long-acting insulin and rapid acting analog) or pre-mix users with A1C \<12.0% OR basal users on long or intermediate acting insulin only with A1C \> 7.0% and \< 12.0%
  • Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, or Admelog
  • Participant agrees to provide their own insulin for the duration of the study
  • Stable doses over the preceding 4 weeks of other glucose-lowering medications as determined by Investigator
  • Stable doses of weight loss medications over the preceding 4 weeks and throughout the study that may affect glycemic control directly and/or indirectly, except for a dose reduction or discontinuation, as determined by Investigator
  • Willing to wear the system continuously throughout the study
  • Deemed appropriate for pump therapy per investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
  • Investigator has confidence that the participant has the cognitive ability and can successfully operate all study devices and can adhere to the protocol
  • Able to read and understand English or Spanish
  • Willing and able to sign the Informed Consent Form (ICF)
  • If female of childbearing potential, willing and able to have pregnancy testing

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (21)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
MAHEC
Coordinator of this site? Confirm its status
AshevilleUnited StatesUnknown status
Emory
Coordinator of this site? Confirm its status
AtlantaUnited StatesUnknown status
University of Colorado
Coordinator of this site? Confirm its status
AuroraUnited StatesUnknown status
Texas Diabetes and Endocrinology
Coordinator of this site? Confirm its status
AustinUnited StatesUnknown status
Joslin Diabetes
Coordinator of this site? Confirm its status
BostonUnited StatesUnknown status
East Coast Institute for Research
Coordinator of this site? Confirm its status
CantonUnited StatesUnknown status
University of North Carolina
Coordinator of this site? Confirm its status
Chapel HillUnited StatesUnknown status
University Diabetes and Endocrine Consultants
Coordinator of this site? Confirm its status
ChattanoogaUnited StatesUnknown status
Ohio State
Coordinator of this site? Confirm its status
ColumbusUnited StatesUnknown status
Henry Ford
Coordinator of this site? Confirm its status
DetroitUnited StatesUnknown status
Diabetes and Thyroid Center
Coordinator of this site? Confirm its status
Fort WorthUnited StatesUnknown status
Physicians East
Coordinator of this site? Confirm its status
GreenvilleUnited StatesUnknown status
East Coast Institute for Research
Coordinator of this site? Confirm its status
JacksonvilleUnited StatesUnknown status
University of Southern California
Coordinator of this site? Confirm its status
Los AngelesUnited StatesUnknown status
Health Partners
Coordinator of this site? Confirm its status
MinneapolisUnited StatesUnknown status
Endocrine Research
Coordinator of this site? Confirm its status
RoswellUnited StatesUnknown status
Diabetes and Glandular Disease Clinic
Coordinator of this site? Confirm its status
San AntonioUnited StatesUnknown status
Sansum Diabetes Research Institute
Coordinator of this site? Confirm its status
Santa BarbaraUnited StatesUnknown status
Albert Einstein College of Medicine
Coordinator of this site? Confirm its status
The BronxUnited StatesUnknown status
Metabolic Research Institute
Coordinator of this site? Confirm its status
West Palm BeachUnited StatesUnknown status
Accellacare
Coordinator of this site? Confirm its status
WilmingtonUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.